Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

4.750 -0.590 (-11.05%)
Streaming Delayed Price Updated: 12:15 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,928
Open 5.070
Bid (Size) 4.620 (300)
Ask (Size) 5.000 (1,400)
Prev. Close 5.340
Today's Range 4.660 - 5.070
52wk Range 3.200 - 6.980
Shares Outstanding 17,025,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
From Avacta Group PLC
Via GlobeNewswire
News headline image
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
From Avacta Group PLC
Via GlobeNewswire

Performance

YTD
+11.2%
+11.2%
1 Month
-6.9%
-6.9%
3 Month
+18.5%
+18.5%
6 Month
+5.3%
+5.3%
1 Year
-10.2%
-10.2%

More News

Read More
News headline image
PPHC Increases 2026 Interim Dividend to $0.117 Per Share
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Public Policy Holding Company, Inc. Announces Q2 2026 Financial Results
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
TierPoint Launches Adapt DDoS Protection
From TierPoint
Via GlobeNewswire
News headline image
PPHC Acquires Florida Government Relations Firm
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Reports 2026 Interim Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC to Report Second Quarter 2026 Financial Results and Present at Upcoming Investor Conference
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
PPHC Strengthens Public Affairs Offering with Hire of Managing Director and Content Specialist
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC Announces Acquisition of Tancredi
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2026 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Leishen Energy Named as the No. 1 Bid Winner for Surface Control Integrated Devices with a Sinopec Oilfield
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
News headline image
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
From Avacta Group PLC
Via GlobeNewswire
News headline image
PPHC to Participate in Stifel’s Ninth Annual Boston Cross Sector 1x1 Conference
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares publicly traded?
Yes, Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is publicly traded.
What exchange does Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trade on?
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is LSE on the Nasdaq Stock Market
What is the current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 4.750
When was Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares last traded?
The last trade of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares was at 09/18/26 12:15 PM ET
What is the market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 80.87M
How many shares of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares are outstanding?
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares has 81M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.